Works by Ito, Takafumi

Results: 64
    1
    2

    Recurrence after ESD curative resection for early gastric cancer.

    Published in:
    Surgical Case Reports, 2021, v. 7, n. 1, p. 1, doi. 10.1186/s40792-020-01089-0
    By:
    • Kamiya, Ayako;
    • Katai, Hitoshi;
    • Ishizu, Kenichi;
    • Wada, Takeyuki;
    • Hayashi, Tsutomu;
    • Otsuki, Sho;
    • Yamagata, Yukinori;
    • Yoshikawa, Takaki;
    • Sekine, Shigeki;
    • Nishi, Tomohiko;
    • Kawasaki, Yuka;
    • Ito, Takafumi;
    • Domoto, Hideharu
    Publication type:
    Article
    3
    4
    5
    6

    PM-MVS: PatchMatch multi-view stereo.

    Published in:
    Machine Vision & Applications, 2023, v. 34, n. 2, p. 1, doi. 10.1007/s00138-023-01380-8
    By:
    • Ito, Koichi;
    • Ito, Takafumi;
    • Aoki, Takafumi
    Publication type:
    Article
    7
    8
    9

    Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).

    Published in:
    PLoS ONE, 2020, v. 15, n. 10, p. 1, doi. 10.1371/journal.pone.0240402
    By:
    • Sofue, Tadashi;
    • Nakagawa, Naoki;
    • Kanda, Eiichiro;
    • Nagasu, Hajime;
    • Matsushita, Kunihiro;
    • Nangaku, Masaomi;
    • Maruyama, Shoichi;
    • Wada, Takashi;
    • Terada, Yoshio;
    • Yamagata, Kunihiro;
    • Narita, Ichiei;
    • Yanagita, Motoko;
    • Sugiyama, Hitoshi;
    • Shigematsu, Takashi;
    • Ito, Takafumi;
    • Tamura, Kouichi;
    • Isaka, Yoshitaka;
    • Okada, Hirokazu;
    • Tsuruya, Kazuhiko;
    • Yokoyama, Hitoshi
    Publication type:
    Article
    10

    Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).

    Published in:
    PLoS ONE, 2020, v. 15, n. 7, p. 1, doi. 10.1371/journal.pone.0236132
    By:
    • Sofue, Tadashi;
    • Nakagawa, Naoki;
    • Kanda, Eiichiro;
    • Nagasu, Hajime;
    • Matsushita, Kunihiro;
    • Nangaku, Masaomi;
    • Maruyama, Shoichi;
    • Wada, Takashi;
    • Terada, Yoshio;
    • Yamagata, Kunihiro;
    • Narita, Ichiei;
    • Yanagita, Motoko;
    • Sugiyama, Hitoshi;
    • Shigematsu, Takashi;
    • Ito, Takafumi;
    • Tamura, Kouichi;
    • Isaka, Yoshitaka;
    • Okada, Hirokazu;
    • Tsuruya, Kazuhiko;
    • Yokoyama, Hitoshi
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29

    Effects of the N/L-Type Calcium Channel Blocker Cilnidipine on Nephropathy and Uric Acid Metabolism in Hypertensive Patients With Chronic Kidney Disease (J- CIRCLE Study).

    Published in:
    Journal of Clinical Hypertension, 2014, v. 16, n. 10, p. 746, doi. 10.1111/jch.12412
    By:
    • Uchida, Shunya;
    • Takahashi, Masato;
    • Sugawara, Masahiro;
    • Saito, Tomoaki;
    • Nakai, Kazuhiko;
    • Fujita, Masami;
    • Mochizuki, Koichi;
    • Shin, Isu;
    • Morita, Takashi;
    • Hikita, Tomoyuki;
    • Itakura, Hironao;
    • Takahashi, Yuko;
    • Mizuno, Shigeki;
    • Ohno, Yasumi;
    • Ito, Kageki;
    • Ito, Takafumi;
    • Soma, Masayoshi
    Publication type:
    Article
    30
    31

    The efficacy and safety of mizoribine for maintenance therapy in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis: the usefulness of serum mizoribine monitoring.

    Published in:
    Clinical & Experimental Nephrology, 2022, v. 26, n. 11, p. 1092, doi. 10.1007/s10157-022-02253-6
    By:
    • Mase, Kaori;
    • Saito, Chie;
    • Usui, Joichi;
    • Arimura, Yoshihiro;
    • Nitta, Kosaku;
    • Wada, Takashi;
    • Makino, Hirofumi;
    • Muso, Eri;
    • Hirawa, Nobuhito;
    • Kobayashi, Masaki;
    • Yumura, Wako;
    • Fujimoto, Shouichi;
    • Nakagawa, Naoki;
    • Ito, Takafumi;
    • Yuzawa, Yukio;
    • Matsuo, Seiichi;
    • Yamagata, Kunihiro
    Publication type:
    Article
    32

    Histopathological classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a nationwide Japanese prospective 2-year follow-up cohort study.

    Published in:
    Clinical & Experimental Nephrology, 2019, v. 23, n. 3, p. 387, doi. 10.1007/s10157-018-1656-1
    By:
    • Yamagata, Kunihiro;
    • Usui, Joichi;
    • Nagata, Michio;
    • Sugiyama, Hitoshi;
    • Sada, Ken-ei;
    • Muso, Eri;
    • Harigai, Masayoshi;
    • Amano, Koichi;
    • Atsumi, Tatsuya;
    • Fujimoto, Shouichi;
    • Yuzawa, Yukio;
    • Kobayashi, Masaki;
    • Saito, Takao;
    • Ito, Takafumi;
    • Hirawa, Nobuhito;
    • Homma, Sakae;
    • Dobashi, Hiroaki;
    • Tsuboi, Naotaka;
    • Ishizu, Akihiro;
    • Arimura, Yoshihiro
    Publication type:
    Article
    33

    Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia.

    Published in:
    Clinical & Experimental Nephrology, 2018, v. 22, n. 3, p. 591, doi. 10.1007/s10157-017-1488-4
    By:
    • Wada, Takashi;
    • Muso, Eri;
    • Maruyama, Shoichi;
    • Hara, Akinori;
    • Furuichi, Kengo;
    • Yoshimura, Kenichi;
    • Miyazaki, Mariko;
    • Sato, Eiichi;
    • Abe, Masanori;
    • Shibagaki, Yugo;
    • Narita, Ichiei;
    • Yokoyama, Hitoshi;
    • Mori, Noriko;
    • Yuzawa, Yukio;
    • Matsubara, Takeshi;
    • Tsukamoto, Tatsuo;
    • Wada, Jun;
    • Ito, Takafumi;
    • Masutani, Kosuke;
    • Tsuruya, Kazuhiko
    Publication type:
    Article
    34
    35

    Performance of polysulfone membrane dialyzers and dialysate flow pattern.

    Published in:
    Clinical & Experimental Nephrology, 2006, v. 10, n. 3, p. 210, doi. 10.1007/s10157-006-0431-x
    By:
    • Nakashima, Ayumu;
    • Ogata, Satoshi;
    • Doi, Shigehiro;
    • Yamahira, Michihiro;
    • Naraki, Satoe;
    • Takasugi, Norihisa;
    • Ohmoto, Toshifumi;
    • Ito, Takafumi;
    • Masaki, Takao;
    • Yorioka, Noriaki
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Treatment with vonoprazan for 3 weeks is not inferior to 8 weeks for the management of gastric ESD: a multicenter noninferiority randomized study.

    Published in:
    Journal of Gastroenterology, 2023, v. 58, n. 4, p. 358, doi. 10.1007/s00535-023-01966-z
    By:
    • Kato, Motohiko;
    • Hosoe, Naoki;
    • Gotoda, Takuji;
    • Kusano, Chika;
    • Kuramochi, Mizuki;
    • Yoshida, Hideo;
    • Kimoto, Yoshiaki;
    • Okamura, Yukishige;
    • Imaeda, Hiroyuki;
    • Ito, Takafumi;
    • Miyamoto, Yasuo;
    • Horii, Toshiki;
    • Mori, Hideki;
    • Morohoshi, Yuichi;
    • Ohno, Akiko;
    • Kishino, Ryohei;
    • Kubosawa, Yoko;
    • Yoshimura, Kenichi;
    • Yahagi, Naohisa;
    • Kanai, Takanori
    Publication type:
    Article
    45
    46
    47
    48
    49
    50